Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 612-618

  Lacey, C J N ^a,b,c   Thompson, H S G ^a,b,c,d   Monteiro, E F ^a,b,c   O'Neill, T ^a,b,c   Davies, M L ^a,b,c   Holding, F P ^a,b,c   Fallon, R E ^a,b,c   Roberts, J St C ^a,b,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d Apax Ptnrs and Co Ventures Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 5; PODOPHYLLOTOXIN; VIRUS VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; WART VIRUS;

ADULT; CONDYLOMATA ACUMINATA; CYTOKINES; DNA, VIRAL; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0033372829     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314616     Document Type: Article

References (29)

1. 1. Gross G, Ikenberg H, Gissmann L, Hagedorn M. Papillomavirus infection of the anogenital region: correlation between histology, clinical picture and virus type. J Invest Dermatol 1985; 85:147-52.
2. 2. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community incidence and clinical picture. Acta Obstet Gynecol Scand 1996; 75:287-90.
3. 3. Munk C, Kjaer SK, Poll PA, Bock JE. Incidence of and risk factors for genital warts among 7091 women aged 20-29 years [abstract 437]. In: Program and abstracts: 16th International Papillomavirus Conference, Siena, Italy, 1997.
4. 4. CDC Division of STD Prevention, Sexually transmitted disease surveillance 1995. Atlanta: Centers for Disease Control and Prevention, 1996.
5. 5. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin Infect Dis 1995;20(suppl I):S91-7.
6. 6. Department of Health. Statistical bulletin - sexually transmitted diseases, England, 1995. London: Government Statistical Service, 1996.
7. 7. Biberstein H. Versuche uber Immunotherapie der Warzen und Kondylome, Klin Wochenschr 1925; 4:638-41.
8. 8. Malison MD, Morris R, Jones LW. Autogenous vaccine therapy for condyloma acuminatum: a double-blind controlled study. Br J Vener Dis 1982; 58:62-5.
9. 9. Jarrett WFH, Smith KT, O'Neil BW, et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 1991; 184:33-42.
10. 10. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WFH, Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993; 74:945-53.
11. 11. Dartmann K, Scharwz E, Gissmann L, Zur Hausen H. The nucleotide sequence and genome organization of human papillomavirus type 11. Virology 1986; 151:124-30.
12. 12. Thompson HSG, Davies ML, Watts MJ, et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 1998; 16:1993-9.
13. 13. Thompson HSG, Davies ML, Holding FP, et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV 6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999; 17:40-9.
14. 14. Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogentic algorithms. J Infect Dis 1994; 170:1077-85.
15. 15. Fennema JSA, van Ameijden EJC, Coutinho RA, van den Hoek JAR. HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. AIDS 1995; 9:1071-8.
16. 16. Aiba S, Rokugo M, Tagami H. Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts. Cancer 1986; 58: 1246-51.
17. 17. Coleman N, Birley HDL, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102:768-74.
18. 18. Han R, Breitburd F, Marche PN, Orth G. Analysis of the sequence variation of the antigen binding domain of DR-α and DQ-α molecules as related to the evolution of papillomavirus-induced warts in rabbits. J Invest Dermatol 1994; 103:376-80.
19. 19. Knowles G, O'Neil BW, Campo MS. Phenotypical characterization of lymphocytes infiltrating papillomas. J Virol 1996;70:8451-8.
20. 20. Selvakumar R, Borenstein LA. Lin YL, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 1995; 69:602-5.
21. 21. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997; 71:8467-74.
22. 22. Selvakumar R, Schmitt A, Iftner T, Ahmed R, Wettstein FO. Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8 cells and persistence of viral DNA after regression, J Virol 1997; 71:5540-8.
23. 23. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991;181:62-9.
24. 24. Chen LP, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992;148:2617-21.
25. 2 cells is epitope and major histocompatibility complex dependent. J Virol 1995;69: 2776-85.
26. 26. Milich DR, Wolf SF, Hughes JL, Jones JE. lnterleukin-12 suppresses auto-antibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proc Natl Acad Sci USA 1995;92:6847-51.
27. 27. Hong K, Greer CE, Ketter N, Van Nest G, Paliard X. Isolation and characterization of human papillomavirus type 6 specific T cells infiltrating genital warts. J Virol 1997;71:6427-32.
28. 28. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
29. 29. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91.